When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron ...